248 related articles for article (PubMed ID: 17652815)
1. Molecular and cellular mechanisms of anthracycline cardiotoxicity.
Chen B; Peng X; Pentassuglia L; Lim CC; Sawyer DB
Cardiovasc Toxicol; 2007; 7(2):114-21. PubMed ID: 17652815
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
Sawyer DB; Peng X; Chen B; Pentassuglia L; Lim CC
Prog Cardiovasc Dis; 2010; 53(2):105-13. PubMed ID: 20728697
[TBL] [Abstract][Full Text] [Related]
3. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine.
Peng X; Chen B; Lim CC; Sawyer DB
Mol Interv; 2005 Jun; 5(3):163-71. PubMed ID: 15994456
[TBL] [Abstract][Full Text] [Related]
4. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
5. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.
Jirkovsky E; Popelová O; Kriváková-Stanková P; Vávrová A; Hroch M; Hasková P; Brcáková-Dolezelová E; Micuda S; Adamcová M; Simůnek T; Cervinková Z; Gersl V; Sterba M
J Pharmacol Exp Ther; 2012 Nov; 343(2):468-78. PubMed ID: 22915767
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
Scully RE; Lipshultz SE
Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
[TBL] [Abstract][Full Text] [Related]
7. [Cardiotoxicity of anthracyclines].
Costache II; Petriş A
Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
[TBL] [Abstract][Full Text] [Related]
8. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
9. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.
Popelová O; Sterba M; Simůnek T; Mazurová Y; Guncová I; Hroch M; Adamcová M; Gersl V
J Pharmacol Exp Ther; 2008 Jul; 326(1):259-69. PubMed ID: 18434588
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
Gianni L; Salvatorelli E; Minotti G
Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
[TBL] [Abstract][Full Text] [Related]
11. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.
Geisberg CA; Sawyer DB
Curr Hypertens Rep; 2010 Dec; 12(6):404-10. PubMed ID: 20842465
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2010 Jan; 23(1):6-10. PubMed ID: 19954191
[TBL] [Abstract][Full Text] [Related]
14. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Henriksen PA
Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
[TBL] [Abstract][Full Text] [Related]
16. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
17. Genotyping the risk of anthracycline-induced cardiotoxicity.
Deng S; Wojnowski L
Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
[TBL] [Abstract][Full Text] [Related]
18. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant defense against anthracycline cardiotoxicity by metallothionein.
Kang YJ
Cardiovasc Toxicol; 2007; 7(2):95-100. PubMed ID: 17652812
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity of cytotoxic drugs.
Schimmel KJ; Richel DJ; van den Brink RB; Guchelaar HJ
Cancer Treat Rev; 2004 Apr; 30(2):181-91. PubMed ID: 15023436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
